Cardiovascular Disease and COVID-19: Insight From Cases With Heart Failure

• Main Authors: Yang Yi, Yanan Xu, Haibing Jiang, Jun Wang
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2021-03-01
• Series: Frontiers in Cardiovascular Medicine
• Subjects: cardiac failure; COVID-19; cardiovascular disease; clinical outcomes; therapeutic strategies; Angiotensin (Ang)-converting enzyme 2
• Online Access: https://www.frontiersin.org/articles/10.3389/fcvm.2021.629958/full

Recent evidence indicates that a large proportion of deaths from coronavirus disease 2019 (COVID-19) can be attributed to cardiovascular disease, including acute myocardial infarction, arrhythmias and heart failure. Indeed, severe infection increases the risk of heart failure among patients with COVID-19. In most patients, heart failure arises from complex interactions between pre-existing conditions, cardiac injury, renin-angiotensin system activation, and the effects of systemic inflammation on the cardiovascular system. In this review, we summarize current knowledge regarding pathogen-driven heart failure occurring during treatment for COVID-19, the potential effects of commonly used cardiovascular and anti-infective drugs in these patients, and possible directions for establishing a theoretical basis for clinical treatment.